Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04743505 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04743505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04743505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 18, 2022
Completion date
December 31, 2029
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non small cell lung cancer